Two Top 50 International Drug Developers Award $3.6 Million in Thorough QT Studies to eResearchTechnology
01 April 2005 - 1:05AM
PR Newswire (US)
Two Top 50 International Drug Developers Award $3.6 Million in
Thorough QT Studies to eResearchTechnology Agreements with
Europe-based and Japan-based Pharmaceutical Organizations
Demonstrate Global Momentum of Regulatory Guidance PHILADELPHIA,
March 31 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT),
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has been awarded two Thorough QT studies
valued at about $3.6 million in cardiac safety monitoring and
services from a Europe-based and a Japan-based international drug
developer for two compounds in clinical trials. The awards cover
two significant Thorough QT studies, for which eRT is providing
comprehensive support, including provision of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data
that is subsequently provided to eRT for analysis. eRT will perform
digital collection, measurement, interpretation, review, and
distribution of cardiac safety data through its EXPeRT workflow
enabled data handling technology, the first solution in production
that was designed explicitly to meet emerging international
regulatory guidance and technical standards. "We are delighted to
have been selected by the sponsors of these two important trials,
which demonstrate the global momentum for implementation of
maturing regulatory guidance and the continued trend toward
Thorough QT studies with extremely robust ECG collection profiles,"
said Scott Grisanti, senior vice president of business development
and chief marketing officer at eRT. "In one case, the sponsor
received value from eRT's Certified Clinical Pharmacology Unit
(CPU) Partner Program, which enables eRT and its partners to offer
turnkey solutions to drug developers. In the other study, eRT was
able to rapidly develop a close working relationship with that
sponsor's preferred provider of CPU services." Based in
Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/)
is a provider of technology and services to the pharmaceutical,
biotechnology and medical device industries on a global basis. The
company is a market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. The
sponsors may cancel these agreements at their sole discretion. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Report on Form 10-K filed with the Securities and
Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT:
Joan Sterlacci, eResearchTechnology, Inc., +1-908-203-6473; or Matt
Hayden, Hayden Communications, +1-858-704-5065, for
eResearchTechnology Web site: http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles